Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1- infection and AIDS

Journal of Immunological Methods

Volumn 231, Issue 1-2, 1999, Pages 223-238

  Marasco, Wayne A ^a   Lavecchio, Joyce ^a   Winkler, Aaron ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

AD, activation domain of Tat; AIDS; ARM, arginine rich motif of Tat; Gene therapy; HIV infection; Intrabodies; Intracellular antibodies

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; TRANSACTIVATOR PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; GENE THERAPY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSACTIVATION; VIREMIA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CLINICAL TRIALS; GENE PRODUCTS, TAT; GENE THERAPY; GIANT CELLS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; MOLECULAR SEQUENCE DATA; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0033499430     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-1759(99)00159-3     Document Type: Article

References (90)

1. Alcami J., Lera T., Folgueira L., Pedraza M.-A., Jacque J.-M., Bachelerie F., Noriega A.R., Hay R.T., Harrich D., Gaylor R., Virelizier J.-L., Seisdedos F.A. Absolute dependence on NF-κB responsive elements for initiation and Tat-mediated amplification of HIV transcription in blood CD4 lymphocytes. EMBO J. 14:1995;1552.
2. Biswas D.K., Ahlers C.M., Dezube B.J., Pardee A.B. Cooperative inhibition of NF-κB and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc. Natl. Acad. Sci. U.S.A. 90:1993;11044.
3. Biswas D.K., Salas T.R., Wang F., Ahlers C.M., Dezube B.J., Pardee A.B. A Tat-induced auto-up-regulatory loop for superactivation of the human immunodeficiency virus type 1 promoter. J. Virol. 69:1995;7437.
4. Blaese R.M., Culver K.W., Miller D.A., Carter C.S., Fleisher T., Clerici M., Shearer G., Chang L., Chiang Y., Tolstoshev P.et al. T lymphocyte-directed gene therapy for ADA SCID: initial trial results after 4 years. Science. 270:1995;475.
5. Bonini C., Ferrari G., Verzeletti S., Servida P., Zappone E., Ruggieri L., Ponzoni M., Rossini S., Mavilio F., Traversari C., Bordignon C. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 276:1997;1719.
6. Buonaguro L., Barillari G., Chang H.-K., Bohan C., Kao V., Morgan R., Gallo R.C., Ensoli B. Effects of the human immunodeficiency virus type 1 Tat protein on the expression of inflammatory cytokines. J. Virol. 66:1992;7159.
7. Buonaguro L., Buonaguro F.M., Giraldo G., Ensoli B. The human immunodeficiency virus type 1 Tat protein transactivates tumor necrosis factor beta gene expression through a TAR-like structure. J. Virol. 68:1994;2677.
8. Carroll R., Martarano L., Derse D. Identification of lentivirus Tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus Type 1 tat gene chimeras. J. Virol. 65:1991;3460.
9. + T cells. Science. 276:1997;273.
10. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 11:1997;1421.
11. Chun T.-W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.-H., Barditch-Crovo P., Siliciano R.F. Quantification of latent tissue reservoirs and totally body viral load in HIV-1 infection. Nature. 387:1997;183.
12. Coffin J.M. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483.
13. AIDS Clinical Trials Group, Collier A.C., Coombs R.W., Schoenfeld D.A., Bassett R.L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V.J., Friedman H.M., Merigan T.C., Reichman R.C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N. Engl. J. Med. 334:1996;1011.
14. Condra J.H. Resisting resistance: maximizing the durability of antiretroviral therapy. Ann. Int. Med. 128:1998;951.
15. Connor R.I., Sheridan K.E., Ceradini D., Choe S., Landau N.R. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J. Exp. Med. 185:1997;621.
16. + T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat. Med. 3:1997;533.
17. Cupp C., Taylor J.P., Khalili K., Amini S. Evidence for stimulation of the transforming growth factor β1 promoter by HIV-1 Tat in cells derived from CNS. Oncogene. 8:1993;2231.
18. Daar E.S., Bai J., Hausner M.A., Majchrowicz M., Tamaddon M., Giorgi J.V. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before serconversion. Ann. Int. Med. 128:1998;827.
19. Dayton A.I., Sodroski J.G., Rosen C.A., Goh W.C., Haseltine W.A. The trans-activator gene of the human T cell lymphotropic virus Type III is required for replication. Cell. 44:1986;941.
20. Emerman M., Malim M. HIV-1 regulatory/accessory genes: keys to unraveling vital and host cell biology. Science. 280:1998;1880.
21. Ensoli B., Barillari G., Salahuddin S.Z., Gallo R.C., Wong-Staal F. Tat protein of HIV-1 simulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature. 345:1990;84.
22. + cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-affinity nerve growth factor receptor (ΔLNGFR) gene. Hum. Gene Ther. 8:1997;1815.
23. Feinberg M.B., Baltimore D., Frankel A.D. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. Proc. Natl. Acad. Sci. U.S.A. 88:1991;4045.
24. Finzi D., Hermankova M., Pierson T., Carruth L.M., Buck C., Chaisson R.E., Quinn T.C., Chadwick K., Margolick J., Brookmeyer R., Gallant J., Markowitz M., Ho D.D., Richman D.D., Siliciano R.F. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 278:1997;1295.
25. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5:1999;512.
26. Fisher A.G., Feinberg M.B., Josephs S.F., Harper M.E., Marselle L.M., Reyes G., Gonda M.A., Aldovini A., Debouk C., Gallo R.C., Wong-Staal F. The trans-activator gene of HTLV-III is essential for virus replication. Nature. 320:1986;367.
27. Frankel A.D., Pabo C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell. 55:1988;1189.
28. Garber M.E., Wi P., KewalRamani V.N., Mayall T.P., Herrmann C.H., Rice A.P., Littman D.R., Jones K.A. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:1998;3512.
29. Glushakova S., Grivel J.-C., Fitzgerald W., Sylwester A., Zimmerberg J., Margolis L.B. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat. Med. 4:1998;346.
30. Goldberg A.L. Functions of the proteasome: the lysis at the end of the tunnel. Science. 268:1995;522.
31. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat. Med. 1:1996;960.
32. + repertoire during antiviral therapy. Nat. Med. 4:1998;215.
33. Goulder P.J.R., Phillips R.E., Colbert R.A., McAdam S., Ogg G., Nowak M.A., Giangrande P., Luzzi G., Morgan B., Edwards A., McMichael A.J., Rowland-Jones S. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat. Med. 3:1997;212.
34. AIDS Clinical Trials Group 320 Study Team, Hammer S.M., Squires K.E., Hughes M.D., Grimes J.M., Demeter L.M., Currier J.S., Eron J.J. Jr., Feinberg J.E., Balfour H.H. Jr., Deyton L.R., Chodakewitz J.A., Fischl M.A. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New Engl. J. Med. 337:1997;725.
35. Havlir D.V., Richman D.D. Viral dynamics of HIV: implications for drug development and therapeutic strategies. Ann. Int. Med. 124:1996;984.
36. AIDS Clinical Trials Group Study 343 Team, Havlir D.V., Marschner I.C., Hirsch M.S., Collier A.C., Tebas P., Bassett R.L., Ioannidis J.P.A., Holohan M.K., Leavitt R., Boone G., Richman D.D. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. New Engl. J. Med. 339:1998;1261.
37. Helland D.E., Welles J.L., Caputo A., Haseltine W.A. Transcellular transactivation by the human immunodeficiency virus Type 1 tat protein. J. Virol. 65:1991;4547.
38. Herrmann C., Rice A. Lentivirus Tat proteins specifically associate with a cellular protein kinase, TAK, that hyperphosphorylates the carboxyl-terminal domain of the large subunit of RNA polymerase II: candidate for a Tat cofactor. J. Virol. 69:1995;1612.
39. Herrmann C.H., Carroll R.G., Wei P., Jones K.A., Rice A.P. Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J. Virol. 72:1998;9881.
40. Howcroft T.K., Strebel K., Martin M.A., Singer D.S. Repression of MHC class I gene promoter activity by two-exon Tat of HIV. Science. 260:1993;1320.
41. Huang L., Bosch I., Hofmann W., Sodroski J., Pardee A.B. Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains. J. Virol. 72:1998;8952.
42. Jones K.A., Peterlin B.M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:1994;717.
43. Kamine J., Chinnadurai G. Synergistic activation of the human immunodeficiency virus type 1 promoter by the viral Tat protein and cellular transcription factor SP1. J. Virol. 66:1992;3926.
44. Kao S.-Y., Calman A.F., Luciw P.A., Peterlin B.M. Anti-termination of transcription within the long terminal repeat of HIV-1 by tat gene product. Nature. 330:1987;489.
45. Kenyon, N.S., Ricordi, C., Gribben, J.G., Nadler, L.M., Zwerner, R.K., Russell, T.R., 1998. High-density particles: a novel, highly efficient cell separation technology. In: Recktenwald, D., Radbruch, A. (Eds.), Cell Separation Methods and Applications. Marcel Dekker, New York, p. 103.
46. Kimata J.T., Kuller L., Anderson D.B., Dailey P., Overbaugh J. Emerging cytopathic and antigenic simian immunodeficiency virus variants influence AIDS progression. Nat. Med. 5:1999;535.
47. Koenig S., Conley A.J., Brewah Y.A., Jones G.M., Leath S., Boots L.J., Davey V., Pantaleo G., Demarest J.F., Carter C., Wannebo C., Yannelli J.R., Rosenberg S.A., Lane H.C. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1:1995;330.
48. + T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat. Med. 4:1998;953.
49. Korber, B. et al. (Eds.), 1995. Human Retroviruses and AIDS. A compilation and analysis of nucleic acids and amino acid sequences. In: Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM.
50. Kuppuswamy M., Subramanian T., Srinivasan A., Chinnadurai G. Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res. 17:1989;3551.
51. Laspia M.F., Rice A.P., Mathews M.B. HIV-1 Tat protein increases transcriptional initiation and stabilizes elongation. Cell. 59:1989;283.
52. LeGuern M., Shioda T., Levy J.A., Cheng-Mayer C. Single amino acid change in Tat determines the different rates of replication of two sequential HIV-1 isolates. Virology. 195:1993;441.
53. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science. 272:1996;1939.
54. Li C.J., Ueda Y., Shi B., Borodyanski L., Huang L., Li Y.-Z., Pardee A.B. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8116.
55. Lie Y.S., Petropoulos C.J. Advances in quantitative PCR technology: 5′ nuclease assays. Curr. Opin. Biotechnol. 9:1998;43.
56. Liu J., Perkins N.D., Schmid R.M., Nabel G.J. Specific NF-6B subunits act in concert with Tat to stimulate human immunodeficiency virus type 1 transcription. J. Virol. 66:1992;3883.
57. Lu Z.-H., Berson J.F., Chen Y.-H., Turner J.D., Zhang T.-Y., Sharron M., Jenks M.H., Wang Z.-X., Kim J., Rucker J., Hoxie J.A., Peiper S.C., Doms R.W. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc. Natl. Acad. Sci. U.S.A. 94:1997;6426.
58. Malim M.H., Hauber J., Fenrick R., Cullen B.R. Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes. Nature. 355:1988;181.
59. Markowitz M., Vesanen M., Tenner-Racz K., Cao Y., Binley J.M., Talal A., Hurley A., Ji X., Chaudhry M.R., Yaman M., Frankel S., Heath-Chiozzi M., Leonard J.M., Moore J.P., Racz P., Nixon D.F., Ho D.D. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus Type 1 infection on viral replication and antiviral immune responses. J. Infect. Dis. 179:1999;525.
60. McGregor D.P., Molloy P.E., Cunningham C., Harris W.J. Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. Mol. Immunol. 31:1994;219.
61. McKnight A., Weiss R.A., Shotton C., Takeuchi Y., Hoshino H., Clapham P.R. Change in tropism upon immune escape by human immunodeficiency virus. J. Virol. 69:1995;3167.
62. Meyerhans A., Cheynier R., Albert J., Seth M., Kwok S., Sninsky J., Morfeldt-Månson L., Asjö B., Wain-Hobson S. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell. 58:1989;901.
63. Mhashilkar A.M., Bagley J., Chen S.Y., Szilvay A.M., Helland D.G., Marasco W.A. Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies. EMBO J. 14:1995;1542.
64. Mhashilkar A.M., Biswas D.K., LaVecchio J., Pardee A.B., Marasco W.A. Inhibition of human immunodeficiency virus Type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-6B antagonists. J. Virol. 71:1997;6486.
65. + mononuclear cells expressing murine and humanized anti-human immunodeficiency virus Type 1 Tat single-chain variable fragment intrabodies. Hum. Gene Ther. 10:1999;1453.
66. Miller A.D., Miller D.G., Garcia J.V., Lynch C.M. Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217:1993;581.
67. Neuveut C., Jeang K.-T. Recombinant human immunodeficiency virus Type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J. Virol. 70:1996;5572.
68. Nowak M.A., May R.M., Phillips R.D., Rowland-Jones S., Lalloo D.G., McAdam S., Klenerman P., Köppe B., Sigmund K., Bangham C.R.M., McMichael A.J. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature. 375:1995;606.
69. Orlando C., Pinzani P., Pazzagli M. Developments in quantitative PCR. Clin. Chem. Lab. Med. 365:1998;255.
70. Ott M., Emiliani S., Van Lint C., Herbein G., Lovett J., Chirmule N., McCloskey T., Pahwa S., Verdin E. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science. 275:1997;1481.
71. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team, Pialoux G., Raffi F., Brun-Vezinet F., Meiffredy V., Flandre P., Gastaut J.-A., Dellamonica P., Yeni P., Delfraissy J.-F., Aboulker J.-P. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. New Engl. J. Med. 339:1998;1269.
72. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:1999;518.
73. + T cells from HIV-infected individuals that express intracellular antibodies against HIV-1 gp120 or Tat. Hum. Gene Ther. 9:1998;487.
74. Poznansky M.C., LaVecchio J., Olszak I.T., Silva-Arietta S., Porter-Brooks J., Brody K., Adams G.B., Ramstedt U., Marasco W.A., Scadden D.T. Inhibition of HIV replication and growth advantage of CD4+ T-cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against HIV-1 tat. Hum. Gene Ther. 10:1999;2505.
75. Rice A.P., Carlotti F. Structural analysis of wild-type and mutant human immunodeficiency virus Type 1 Tat proteins. J. Virol. 64:1990;6018.
76. Riddell S.R., Elliott M., Lewinsohn D.A., Gilbert M.J., Wilson L., Manley S.A., Lupton S.D., Overell R.W., Reynolds T.C., Corey L., Greenberg P.D. T-cell mediated rejection of gene modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. 2:1996;216.
77. Riley J.L., Carroll R.G., Levine B.L., Bernstein W., St. Louis D.C., Weislow O.S., June C.H. Intrinsic resistance to T cell infection with HIV Type 1 induced by CD28 costimulation. J. Immunol. 158:1997;5545.
78. Rock K.L. A new foreign policy: MHC class I molecules monitor the outside world. Immunol. Today. 17:1996;131.
79. Ruben S., Perkins A., Purcell R., Joung K., Sia R., Burghoff R., Haseltine W.A., Rosen C.A. Structural and functional characterization of human immunodeficiency virus tat protein. J. Virol. 63:1989;1.
80. + T lymphocytes. Gene Ther. 3:1996;695.
81. Sastry K.J., Reddy R.H.R., Pandita R., Totpal K., Aggarwal B.B. HIV-1 Tat gene induces tumor necrosis factor B (lymphotoxin) in human B-lymphoblastoid cell line. J. Biol. Chem. 265:1990;20091.
82. Shafer R.W., Winters M.A., Palmer S., Merigan T.C. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Int. Med. 128:1998;906.
83. Valvatne H., Szilvay A.M., Helland D.E. A monoclonal antibody defines a novel HIV Type 1 Tat domain involved in trans-cellular trans-activation. AIDS Res. Human Retroviruses. 12:1996;611.
84. Verzeletti S., Bonini C., Marktel S., Nobili N., Ciceri F., Traversari C., Bordignon C. Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. Hum. Gene Ther. 9:1998;2243.
85. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 246:1989;1606.
86. Wei P., Garber M.E., Fang S.-M., Fischer W.H., Jones K.A. A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell. 92:1998;451.
87. Westendorp M.O., Li-Weber M., Frank R.W., Krammer P.H. Human immunodeficiency virus type 1 Tat upregulates interleukin-2 secretion in activated T cells. J. Virol. 68:1994;4177.
88. Westendorp M.O., Frank R., Ochsenbauer C., Stricker K., Dhein J., Walczak H., Debatin K.M., Krammer P.H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 275:1995;497.
89. Wolinsky S.M., Korber B.T.M., Neumann A.U., Daniels M., Kunstman K.J., Whetsell A.J., Furtado M.R., Cao Y., Ho D.D., Safrit J.T., Koup R.A. Adaptive evolution of human immunodeficiency virus-Type 1 during the natural course of infection. Science. 272:1996;537.
90. Wong J.K., Hezareh M., Ghnthard H.F., Havlir D.V., Ignacio C.C., Spina C.A., Richman D.D. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science. 278:1997;1291.